Company research
Kraig Biocraft Laboratories, Inc.
CIK 1413119Updated Sep 25, 2026
SecurityKBLB · OTC · equity
Name history
Kraig Biocraft Laboratories, Inc · through May 20, 2025
KBLB price & chart
Loading TradingView…
OTC:KBLB on TradingView ↗In the news
These Companies Just Dropped Major Growth Catalysts ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 2,565,540Source | 1,505,333Source | 3,232,822Source | 4,570,920Source |
| Property, Plant and Equipment, NetUSD | 25,003Source | 44,721Source | 66,640Source | 87,861Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 1,790,236Source | 673,264Source | 2,551,834Source | — |
| Inventory, NetUSD | 29,067Source | 6,884Source | 6,884Source | 6,580Source |
| Assets, CurrentUSD | 1,868,641Source | 740,285Source | 2,573,620Source | 3,983,441Source |
| Operating Lease, Right-of-Use AssetUSD | 170,463Source | 86,088Source | 95,808Source | 58,849Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 10,564,498Source | 9,654,954Source | 8,939,978Source | 8,092,780Source |
| Stockholders’ equity: | ||||
| Additional Paid in CapitalUSD | 12,434,886Source | 12,290,687Source | 11,354,213Source | 10,834,729Source |
| Retained Earnings (Accumulated Deficit)USD | -56,709,072Source | -53,085,719Source | -49,686,780Source | -46,657,000Source |
| Stockholders' Equity Attributable to ParentUSD | -7,998,958Source | -8,149,621Source | -5,707,156Source | -3,521,860Source |
| Liabilities and EquityUSD | 2,565,540Source | 1,505,333Source | 3,232,822Source | 4,570,920Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 10,445,245Source | 9,614,428Source | 8,885,610Source | 8,072,083Source |
| Operating Lease, Liability, CurrentUSD | 51,909Source | 46,948Source | 41,789Source | 39,200Source |
| Operating Lease, Liability, NoncurrentUSD | 119,253Source | 40,526Source | 54,368Source | 20,697Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | — | — | — | 107,882Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in InventoriesUSD | 22,183Source | — | 304Source | 6,580Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -1,788,970Source | -1,839,086Source | -1,244,483Source | -1,887,187Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 438,042Source | -4,240Source | -6,399Source | -5,021Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 5,395Source | 4,240Source | 6,399Source | 5,021Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 2,467,900Source | -35,244Source | -60,000Source | 3,399,864Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 1,116,972Source | -1,878,570Source | -1,310,882Source | 1,507,656Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 87,285Source | — | — | — |
| Amortization of Debt Issuance CostsUSD | — | — | — | 1,111,580Source |
| DepreciationUSD | 25,113Source | 26,159Source | 27,620Source | 28,103Source |
| Gain (Loss) on Sale of Assets and Asset Impairment ChargesUSD | 200,433Source | — | — | 0Source |
| General and Administrative ExpenseUSD | 1,958,768Source | 1,747,585Source | 1,454,295Source | 825,460Source |
| InterestExpenseNonoperatingUSD | 570,709Source | 529,603Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -3,623,353Source | -3,398,939Source | -3,029,780Source | -3,842,014Source |
| Nonoperating Income (Expense)USD | — | -324,378Source | -414,986Source | -1,720,671Source |
| Operating ExpensesUSD | 3,374,793Source | 3,074,561Source | 2,614,794Source | 2,121,343Source |
| Other Nonoperating Income (Expense)USD | -248,560Source | — | — | — |
| Realized Investment Gains (Losses)USD | 233,028Source | — | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -3,374,793Source | -3,074,561Source | -2,614,794Source | -2,121,343Source |
| Other Nonoperating Income (Expense)USD | -248,560Source | — | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -3,623,353Source | -3,398,939Source | -3,029,780Source | -3,842,014Source |
| Net Income (Loss) Attributable to ParentUSD | -3,623,353Source | -3,398,939Source | -3,029,780Source | -3,842,014Source |
| Earnings Per Share, BasicUSD per share | 0Source | 0Source | 0Source | 0Source |
| Earnings Per Share, DilutedUSD per share | 0Source | 0Source | 0Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 1,059,485,670Source | 1,038,374,219Source | 1,033,122,597Source | 974,307,366Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 1,059,485,670Source | 1,038,374,219Source | 1,033,122,597Source | — |
| Interest Expense (non-operating)USD | 570,709Source | 529,603Source | — | — |
| Additional Financial Items | ||||
| General and Administrative ExpenseUSD | 1,958,768Source | 1,747,585Source | 1,454,295Source | 825,460Source |
| Interest and Other IncomeUSD | 11,518Source | 71,396Source | — | — |
| Interest Expense, DebtUSD | — | — | — | 153,955Source |
| Interest Income, OperatingUSD | — | — | 109,559Source | — |
| Nonoperating Income (Expense)USD | — | -324,378Source | -414,986Source | -1,720,671Source |
| Operating ExpensesUSD | 3,374,793Source | 3,074,561Source | 2,614,794Source | 2,121,343Source |
| Other IncomeUSD | 200,433Source | — | — | — |
| Realized Investment Gains (Losses)USD | 233,028Source | — | — | — |
| Research and Development ExpenseUSD | 165,758Source | 164,374Source | 237,871Source | 176,431Source |
Offerings
Registration 333-284773
Filing attachments
ex107.htm · S-1 · 2025-02-07
EX-FILING FEES 3 ex107.htm CALCULATION OF FILING FEE TABLES Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) Kraig Biocraft Laboratories, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Maximum Aggregate Offering Price Fee Rate A…
Read attachment ↗ex99-1.htm · 8-K · 2025-01-21
EX-99.1 3 ex99-1.htm Exhibit 99.1 Kraig Biocraft Laboratories Secures $10 Million SEPA to Support Spider Silk Production Growth and Commercialization ANN ARBOR, Mich., - January 21, 2025 - Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), a leading developer of spider silk-based fibers, announces that it has secured $10 million in a standby equity purchase agreement (“SEPA”) with YA II PN, Ltd. (“Yorkville”). This agreement will provide the Company with access…
Read attachment ↗